Interestingly, today Reach Pharmaceuticals has announced that the TGA has granted dexrazoxane Orphan Designation in Australia.
Reach have 6 months now I believe to submit their registration dossier to the TGA for evaluation.
Whilst it doesn't have a direct impact on RAC I do find it interesting that the noise around cardio-oncology and cardioprotection is starting to be amplified globally. RAC couldn't be better positioned to become a global leader in this space. Looking forward to seeing how the team plan to execute on cardio-oncology in the new strategy.
Interestingly, today Reach Pharmaceuticals has announced that...
-
- There are more pages in this discussion • 326 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.87 |
Change
0.005(0.27%) |
Mkt cap ! $316.8M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.87 | $1.85 | $8.774K | 4.715K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1783 | $1.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.88 | 198 | 1 |
View Market Depth
| Last trade - 11.38am 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |